Compare SRCE & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRCE | PHVS |
|---|---|---|
| Founded | 1863 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 1995 | 2020 |
| Metric | SRCE | PHVS |
|---|---|---|
| Price | $76.25 | $33.17 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $74.50 | $41.82 |
| AVG Volume (30 Days) | 99.5K | ★ 297.8K |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.37% | N/A |
| EPS Growth | ★ 19.59 | N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.29 | N/A |
| Revenue Next Year | $3.16 | N/A |
| P/E Ratio | $47.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $56.89 | $16.72 |
| 52 Week High | $79.08 | $33.33 |
| Indicator | SRCE | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 55.10 | 62.11 |
| Support Level | $71.36 | $24.73 |
| Resistance Level | N/A | $33.33 |
| Average True Range (ATR) | 1.45 | 1.51 |
| MACD | 0.18 | 0.14 |
| Stochastic Oscillator | 55.42 | 88.69 |
1st Source Corp provides specialized financing services for construction equipment, aircraft, and vehicle types through its Specialty Finance activities. The company offers commercial, small business, agricultural, and real estate loans, along with commercial leasing, treasury management, and payment services, including Fedwires, ACH, and merchant services. It also provides Renewable Energy Financing for commercial solar projects, a full range of consumer banking products, Trust and Wealth Advisory Services, and insurance products. The company operates in the commercial banking segment, which provides commercial and consumer banking services, trust and wealth advisory services, and insurance to individual and business clients across its markets.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.